超声引导间质性激光动力学疗法治疗肝癌新方法

超声引导间质性激光动力学疗法治疗肝癌新方法福建医学院附属二院邮政编码362000吕国荣，陈骥厦门大学抗癌研究中心曾超英，杨栋，黄萍有关超声引导间质性激光动力学疗法治疗肝癌国内外尚未见报道。本文报道11例采用该技术临床应用的经验并探讨其临床应用价值。原...福建省85攻关项

合成气制低碳混合醇耐硫钼基催化剂的制备研究

本文考察不同制备方法和制备程序制得之MoS_x-K~+/SiO_2催化剂对合成气转化为低碳混合醇的催化性能,探讨不同助剂(包括K_2CO_3,KF,KCl等)对催化剂活性和选择性的影响,首次报道以K_2MoS_4作为前驱物料制得的MoS_x-K~+/SiO_2催化剂具有与(NH_4)_2MoS_4-K_2CO_3/SiO_2衍生得到的催化剂几乎一样高的催化活性和选择性,其结果为具有实用意义的催化剂的研制提供依据

合成气制低碳混合醇耐硫钼基催化剂的制备研究

本文考察不同制备方法和制备程序制得之MoS_x-K~+/SiO_2催化剂对合成气转化为低碳混合醇的催化性能,探讨不同助剂(包括K_2CO_3,KF,KCl等)对催化剂活性和选择性的影响,首次报道以K_2MoS_4作为前驱物料制得的MoS_x-K~+/SiO_2催化剂具有与(NH_4)_2MoS_4-K_2CO_3/SiO_2衍生得到的催化剂几乎一样高的催化活性和选择性,其结果为具有实用意义的催化剂的研制提供依据

合成气制混合醇硫化钼基催化剂的谱学表征

利用XRD、XPS和TPD等谱学方法对合成气制混合醇硫化钼基催化剂活性相作了表征研究。实验结果表明,碱助的MoS_x-K~+/SiO_2催化剂工作表面生成了Mo-S-K新相,很可能是催化活性相;表面钼物种主要是Mo~(4+),硫除了以S~(2-)作为主要硫物种之外,还观测到低价硫阴离子物种S~-或[s—s]~(2-)。随着碱性钾盐助剂添加量的增加,[s—s]~(2-)物种的浓度下降,H_2吸附量相应减少,这同催化剂的选择性由烃向醇的转变有着密切的联系

Mo/HZSM-5基甲烷非氧化脱氢芳构化催化剂的TPD及TPR研究

在Ｍｏ／ＨＺＳＭ－５基甲烷非氧化脱氢芳构化催化剂中加入促进剂ＺｎＳＯ４，使该催化剂的活性和操作稳定性大为改善．对非促进的Ｍｏ／ＨＺＳＭ－５和促进型的Ｍｏ－ＺｎＳＯ４／ＨＺＳＭ－５甲烷芳构化催化剂的ＮＨ３－ＴＰＤ研究结果表明，促进剂ＺｎＳＯ４的加入大大提高了催化剂表面的Ｂ－酸位浓度；这种Ｂ－酸位能较稳定地存在于催化剂表面，不易流失；催化剂表面高浓度Ｂ－酸位的稳定存在是其甲烷非氧化脱氢催化活性显著提高的关键因素．Ｈ２－ＴＰＲ结果显示，过高的焙烧温度不仅不利于维持催化剂的表面酸性位（尤其是Ｂ－酸位）的浓度，还可能导致催化剂表面Ｍｏ物种的聚集和ＭｏＯ３微晶的生成，使同一Ｍｏ负载量的催化剂中可还原至较低价态的Ｍｏ物种所占比例下降

Long-term Follow-up Results of 70 Liver Cancer Cases Received Ultrasound Guided Percutaneous PDT

目的　分析光动力治疗肝癌的临床表现和远期疗效 ,探讨疗效影响因素和治疗适应证 ,为临床推广应用提供参考数据。方法　肝癌患者 70例 ,其中小肝癌 2例 ,大肝癌 6 8例。均经B超、CT定位 ,甲胎蛋白 (AFP)定量 ,病理组织学确诊。治疗前 48h ,患者行血卟啉衍生物 (HpD)皮试 ,阴性者按每公斤体重 5mg静脉给药。治疗时 ,在B超引导下 ,用 18G肝穿针经皮穿刺将石英光纤引导入肝肿瘤内进行光辐照。激光器为氩离子激光泵浦染料激光器系统 ,激光波长 6 30nm ,光纤末端为 1cm长柱状弥散头 ,输出功率 30 0～ 35 0mW ,每一照射点能量累积约 2 2 0J,肿瘤内实行多点照射。治疗后 1周 ,检查血常规、肝功能、AFP及B超 ,一个月后 ,行肝穿活检。多次治疗间歇时间为 1个月。结果　 70例肝癌行 170次治疗 ,其中接受 1次治疗 30例 ,多次治疗 40例。 1次治疗组 1年生存率 10 % ,无生存 2年者 ;2次治疗组 1年生存率 5 0 % ,2年以上生存率 8% ;3次以上治疗组 1年生存率 82 % ,2年生存率 5 0 % ,3年生存率 32 % ,其中 3例存活5年以上。全组只有 18%的患者出现治疗后短期内一过性ALT、AST轻度升高 (<5 0U)和TBIL轻度升高 ,余未见明显异常。随访患者 1～ 5年 ,未见肝功能远期受损。病人接受治疗后 ,只有 17%出现低热 3～ 4天 ,30 %的Objective To investigate the long-term follow-up results of ultrasound-guided percutaneous PDT for liver cancer and to evaluate the efficacy and safety of this technique. Methods 70 patients with liver cancers, including 2 small tumors and 68 large tumors, were examined by ultrasound, CT, AFP assay, and diagnosed by histopatholopy of needle biopsy. The patients received injection of hematoporphyrin derivative(HPD) i.v. in a dose of 5 mg/kg body weight 48 h prior to laser irradiation. An argon laser pumped dye laser system was used to give a CW laser beam at 630 nm. The light beam was split and coupled into three optical fibers. An ultrasound-guided percutaneous liver puncture was performed and optical fibers were inserted into the tumors via 18G needles. Efforts were made to ensure that irradiation points were distributed in entire tumor volume and a light output of 300～350 mW for 12 minutes per point was used. The patients were examined with routine blood test, liver functions, AFP assay and USG at one week after treatment. A month later they were reexamined by needle biopsy and received next PDT treatment. Results Total 170 treatments were performed in the 70 patients. Among them 30 cases were treated for only once, 12 cases twice, 12 cases 3 times, and 16 cases 4 times or more. All 70 cases were followed up for 1-5 years. The results showed that multiple treatment is more effective than single treatment. The 1-, 2-and 3-years survival rate was 10%, 0, 0 in the group by single treatment, respectively, 50%, 8% and 8% in the group treated twice, and 82%, 50% and 30% in the group treated by 3 or more time, respectively. Three patients from the last group have already been surviving for longer than 5 years. Slight increase of ALT, AST and total bilirubin occurred in only 18%, and mild fever occurred in 17% of the 70 cases for 3-4 days shortly after PDT treatment. No severe complications due to PDT such as severe hemorrhage after liver puncture, hepatic failure, biliary peritonitis or long-lasting liver dysfunctions were observed in our group. Conclusions Photodynamic therapy is effective and safe for the treatment of liver cancers including those following hepatic resection or those failed after embolic chemotherapy by hepatic artery infusion. However, we would suggest that single PDT treatment is not enough and repeated PDT treatments are recommended in order to obtain a significant therapeutic effect to patients with large liver cancers.福建省“95”重点科技项

促进型甲酸甲酯氢解制甲醇铜基催化剂的研究

研制开发了一种耐ＣＯ低温高效四组分（Ｃｕ－Ｃｒ－Ｍｎ－Ｎｉ）改进铜铬催化剂，其原料合成气中ＣＯ允许含量可高达１３Ｖ％；在常压，４１３Ｋ，原料气Ｈ２／ＭＦ＝４／１（ｖ／ｖ），流速为１８００ｍＬ／ｈｇｃａｔａｌ．的反应条件下，ＭＦ转化率高达９９．８％，甲醇选择性为９９．９％（在相同反应条件下二组分的Ｃｕ－Ｃｒ催化剂上ＭＦ转化率仅为７３．１％，甲醇选择性为９８．０％），当向原料气中添加１３．１Ｖ％ＣＯ时，ＭＦ转化率仍可以稳定达到９５．９％，甲醇选择性为９６．３％．实验结果表明，ＣＯ导致催化剂失活的重要原因之一是ＣＯ导致Ｃｕ＋深度还原为Ｃｕ０，减少催化剂的活性中

轮状病毒VP4~*高聚体的制备及其免疫保护性评价

在前期工作中发现,截短的轮状病毒VP4~*蛋白(aa26–476)在大肠杆菌中能够以可溶形式表达,且在小鼠模型中具有较高的免疫原性和免疫保护性。本研究通过颗粒化进一步提高VP4~*蛋白的免疫保护性。通过37℃水浴加热处理24h使VP4~*蛋白多聚化,通过高效液相色谱、透射电镜、分析超离等分析VP4~*蛋白颗粒化程度,通过酶联免疫吸附试验分析颗粒化对VP4~*蛋白与中和抗体反应性的影响;通过差示量热法分析VP4~*高聚体的热稳定性;最后,通过小鼠母传抗体模型研究颗粒化对VP4~*免疫原性和免疫保护性的影响。结果表明,VP4~*蛋白高聚体结构均一,并且相比三聚体,具有更高热稳定性和中和抗体结合活性;在内毒素<20 EU/mg的条件下,与铝佐剂混合,刺激小鼠产生更高滴度的中和抗体;对轮状病毒导致的腹泻具有更高的免疫保护性。综上所述,VP4~*高聚体的研究为轮状病毒基因工程亚单位疫苗的研制提供了更广阔的思路。国家自然科学基金(No.81501741);;福建省科学技术创新平台(No.2014Y2004)资助~

Ultrasound Guided Percutaneous PDT For Advanced Liver Cancer A Report of 30 Cases

为探讨治疗中晚期肝癌的理想方法，扩大和发展光动力疗法，自1994年6月起，我们应用光动力疗法（PdT）治疗中晚期肝癌30例，其中肝细胞癌28例、腺癌2例。肿瘤直径7~10CM的13例、10CM以上至16CM的17例。伴肺转移5例、骨转移5例、门静脉或腔静脉浸润4例。首次治疗19例、其他方法治疗无效或复发者11例。本研究采用氩激光泵浦染料激光器系统，获得630nM波长的连续波治疗光。光敏剂选用血卟啉衍生物（HPd）。治疗时通过b超引导经皮肝穿，将光纤导入肿瘤组织中布点照射。治疗后未见肝功能明显损伤，未出现肝穿出血、腹膜炎等严重并发症，没有一个月内病情恶化者。有14例患者只作一次治疗，其中5例出院后失访；另9例肿瘤部分缓解率为22%。16例患者接受二、三次治疗，肿瘤部分缓解率达到62%。随访病例中有8例已存活1年以上。patients with advanced liver cancer were treated by interstitial photodynamic therapy (PDT).These included 28 hepatocellular carcinoma and two adenocarcinoma, 19 primary tumors and 11 recurred Following other treatments.The diameter of tumors were 7 10 cm in 13 cases and 10 16 cm in 17 cases.In this study, an argon laser pumped dye laser system was used to give a CW laser beam at 630 nm which was split and coupled into three optical Fibers.The patients received injection of photosensitizer of hematoporphyrin derivative (HpD) i.v.at a dose of 5 mg/kg body weight 48 h prior to laser irradiation.Then the Fibers were inserted into tumor by ultrasonic visualization guided percutaneous liver puncture.The inserted irradiation points were spaced in entire tumor volume and the tumor was irradiated with a light output power of 300 mW For 12 minuts per point.Totally 52 treatments were perFormed in 30 patients.Among them, 14 cases were treated by only one time and 16 cases 2 or 3 times.The Follow up were carried out in 25 cases For 3 18 months.The results show that signiFicant remission was 22% (2/9) in those patients by only one treatment and 62% (10/16) in those by 2 or 3 treatments.The reduction rate of tumor size was over 90% in Five out of six cases aFter 3 treatments.8 patients have been surviving over one year.No obvious change was Found in all patients examined by liver Function test, renal Function test and blood routine examination.The level of AFP depicted a descending tendency aFter PDT.Our Findings indicate that PDT is eFFective and saFe For the treatment of large liver cancers including those recurred Following hepatic resection and those Failed in hepatic artery inFusion embolic chemotherapy.福建省“八五”攻关资

改进型铜基甲醇合成催化剂NC208的DTA研究

对改进型铜基催化剂进行了研究，活性评价结果表明，改进型铜基甲醇合成催化剂ＮＣ２０８（Ｃｕ－Ｚｎ－Ａｌ－Ｍ１２）初始活性比工业催化剂Ｃ２０７（Ｃｕ－Ｚｎ－Ａｌ）提高约１８％；耐热试验后比Ｃ２０７提高约４６％。两种催化剂的ＤＴＡ对比试验显示，工作态ＮＣ２０８催化剂热稳定性明显优于Ｃ２０７；ＮＣ２０８催化剂前驱体含Ｃｕ（ＮＯ３）２·３Ｃｕ（ＯＨ）２、Ｚｎ５（ＯＨ）６（ＣＯ３）２和（ＣｕＺｎ）（ＯＨ）２ＣＯ３等成分比Ｃ２０７多，其分解温度小于３５０℃；ＮＣ２０８催化剂还原最高温度为２３５℃